

**Condensed Consolidated Statements of Earnings (Unaudited)**

Dollars in millions, except per share data

	Three months ended	
	09/30/2023	09/30/2022
Net sales	\$ 1,386	\$ 1,740
Cost of products sold	854	1,114
Gross profit	532	626
Selling and administrative expenses	276	261
Advertising costs	165	161
Research and development costs	29	32
Interest expense	21	22
Other (income) expense, net	12	34
Earnings before income taxes	29	116
Income tax expense	4	29
Net earnings	25	87
Less: Net earnings attributable to noncontrolling interests	3	2
Net earnings attributable to Clorox	\$ 22	\$ 85
Net earnings per share attributable to Clorox		
Basic net earnings per share	\$ 0.17	\$ 0.69
Diluted net earnings per share	\$ 0.17	\$ 0.68
Weighted average shares outstanding (in thousands)		
Basic	123,973	123,339
Diluted	124,650	123,914

## Reportable Segment Information

(Unaudited)

Dollars in millions

	Net sales		
	Three months ended		
	9/30/2023	9/30/2022	% Change <sup>(1)</sup>
Health and Wellness	\$ 504	\$ 657	(23)%
Household	325	423	(23)
Lifestyle	229	320	(28)
International	270	285	(5)
Corporate and Other <sup>(2)</sup>	58	55	5
Total	<u>\$ 1,386</u>	<u>\$ 1,740</u>	<u>(20)%</u>
	Segment adjusted EBIT		
	Three months ended		
	9/30/2023	9/30/2022	% Change <sup>(1)</sup>
Health and Wellness	\$ 104	133	(22)%
Household	(4)	22	(118)
Lifestyle	19	60	(68)
International	34	23	48
Corporate and Other	(62)	(63)	(2)
Total	<u>\$ 91</u>	<u>\$ 175</u>	<u>(48)%</u>
Interest income	10	2	
Interest expense	(21)	(22)	
Cyberattack costs <sup>(3)</sup>	(24)	—	
Streamlined operating model <sup>(4)</sup>	—	(19)	
Digital capabilities and productivity enhancements investment <sup>(5)</sup>	(27)	(20)	
Earnings before income taxes	<u>\$ 29</u>	<u>\$ 116</u>	<u>(75)%</u>

<sup>(1)</sup> Percentages based on rounded numbers.

<sup>(2)</sup> Corporate and Other includes the Vitamin, Minerals and Supplements business.

<sup>(3)</sup> Represents costs related to the cyberattack of \$24 (\$18 after tax) for the three months ended Sept. 30, 2023.

<sup>(4)</sup> Represents restructuring and related costs, net for implementation of the streamlined operating model of \$0 and \$19 (\$14 after tax) for the three months ended Sept. 30, 2023, and 2022, respectively.

<sup>(5)</sup> Represents expenses related to the company's digital capabilities and productivity enhancements investment of \$27 (\$21 after tax) and \$20 (\$15 after tax) for the three months ended Sept. 30, 2023, and 2022, respectively.

**Condensed Consolidated Balance Sheets**

Dollars in millions

	9/30/2023	6/30/2023	9/30/2022
	(Unaudited)		(Unaudited)
<b>ASSETS</b>			
Current assets			
Cash and cash equivalents	\$ 518	\$ 367	\$ 278
Receivables, net	581	688	612
Inventories, net	710	696	755
Prepaid expenses and other current assets	102	77	118
Total current assets	1,911	1,828	1,763
Property, plant and equipment, net	1,317	1,345	1,322
Operating lease right-of-use assets	328	346	336
Goodwill	1,246	1,252	1,546
Trademarks, net	541	543	685
Other intangible assets, net	162	169	190
Other assets	486	462	311
Total assets	\$ 5,991	\$ 5,945	\$ 6,153
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>			
Current liabilities			
Notes and loans payable	\$ 347	\$ 50	\$ 348
Current operating lease liabilities	88	87	78
Accounts payable and accrued liabilities	1,678	1,659	1,584
Income Taxes Payable	115	121	—
Total current liabilities	2,228	1,917	2,010
Long-term debt	2,478	2,477	2,475
Long-term operating lease liabilities	290	310	308
Other liabilities	837	825	805
Deferred income taxes	27	28	59
Total liabilities	5,860	5,557	5,657
Commitments and contingencies			
Stockholders' equity			
Preferred stock	—	—	—
Common stock	131	131	131
Additional paid-in capital	1,246	1,245	1,193
Retained earnings	299	583	832
Treasury stock	(1,219)	(1,246)	(1,315)
Accumulated other comprehensive net (loss) income	(494)	(493)	(515)
Total Clorox stockholders' (deficit) equity	(37)	220	326
Noncontrolling interests	168	168	170
Total stockholders' equity	131	388	496
Total liabilities and stockholders' equity	\$ 5,991	\$ 5,945	\$ 6,153